Immunome (NASDAQ:IMNM) Reaches New 1-Year Low - Here's What Happened

Immunome, Inc. (NASDAQ:IMNM - Get Free Report)'s share price reached a new 52-week low on Tuesday . The stock traded as low as $8.12 and last traded at $8.15, with a volume of 960264 shares changing hands. The stock had previously closed at $8.18.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Guggenheim cut their price target on Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Lifesci Capital started coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 target price for the company. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Stephens reissued an "overweight" rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $25.50.

Immunome Price Performance

The firm has a market cap of $623.87 million, a price-to-earnings ratio of -0.88 and a beta of 1.93. The business's 50-day moving average price is $9.67 and its two-hundred day moving average price is $11.44.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, sell-side analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Remove Ads

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall bought 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares of the company's stock, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Philip Tsai purchased 12,300 shares of the stock in a transaction on Monday, March 24th. The shares were purchased at an average cost of $8.42 per share, with a total value of $103,566.00. Following the transaction, the chief technology officer now owns 33,300 shares of the company's stock, valued at $280,386. This trade represents a 58.57 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 169,300 shares of company stock worth $1,323,536 in the last 90 days. 8.60% of the stock is owned by company insiders.

Institutional Trading of Immunome

A number of institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in Immunome in the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS purchased a new stake in Immunome during the 4th quarter worth $75,000. AlphaQuest LLC increased its holdings in Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Immunome in the fourth quarter worth about $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.